EC Approves Wegovy Pill, First Oral GLP-1 in EU

Key Takeaways

• EC authorised Wegovy pill (oral semaglutide 25 mg) for BMI ≥30, or BMI ≥27 with ≥1 weight-related comorbidity, plus diet and activity.
• It is the first GLP-1 tablet approved for obesity/overweight in the EU, per Novo.
• OASIS 4 showed ~17% mean weight loss versus ~3% placebo; ~1 in 3 reached ≥20% weight loss.
• EC also approved Wegovy 7.2 mg injectable in a single-dose pen (company cites ~21% weight loss).

Wegovy pill EU approval at a glance

Field	Detail
Product	Wegovy pill (oral semaglutide 25 mg once daily)
Company	Novo Nordisk
Regulator	European Commission marketing authorisation (15 July 2026)
Population	Adults with obesity or overweight + ≥1 weight-related comorbidity
Key trial	OASIS 4 (64 weeks; n=307)
Key efficacy	~17% mean weight loss vs ~3% placebo
Also approved	Wegovy 7.2 mg single-dose injection pen

What exactly was authorised?

Novo said the Commission granted marketing authorisation for Wegovy pill for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity. The decision follows the EMA CHMP positive opinion in May 2026.

Source: Novo Nordisk's 15 July GlobeNewswire EC approval release.

What did OASIS 4 show?

OASIS 4 was a 64-week Phase 3b trial of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity or overweight plus comorbidity. Novo reported approximately 17% mean weight loss versus 3% with placebo under lifestyle intervention, with about one-third achieving 20% or greater weight loss.

Related oral semaglutide obesity protocols include ClinicalTrials.gov NCT05564117. Adverse-event discontinuations were nearly comparable to placebo at 6.9% versus 5.9%, the company said.

How does this relate to prior CHMP coverage?

NovaPharma previously covered the committee stage in EMA's CHMP recommendation for oral Wegovy. The July Commission decision converts that opinion into centralised EU authorisation and also adds the higher-dose 7.2 mg injectable pen.

EMA committee context continues in monthly CHMP pages on ema.europa.eu.

What remains uncertain?

National pricing, reimbursement, and supply sequencing will determine launch timing by Member State. Cardiovascular-outcome claims for the oral 25 mg tablet versus injectable Wegovy labels differ by jurisdiction; clinicians should follow the EU SmPC once published. Real-world adherence for fasting/absorption rules of oral semaglutide needs monitoring.

Related NovaPharma coverage

• EMA's CHMP Recommends Oral Wegovy Approval
• EMA Endorses Novo Nordisk's Wegovy for Weight Loss
• EASD 2026 Preview: Milan Diabetes Catalysts

Frequently Asked Questions

Primary Sources

1. GlobeNewswire: Novo Nordisk — EC approval of Wegovy pill — 15 July 2026
2. ClinicalTrials.gov: oral semaglutide obesity study NCT05564117
3. EMA: Committee for Medicinal Products for Human Use (CHMP)
4. Novo Nordisk corporate site